Thursday, August 21, 2014 Last update: 9:33 PM
FreshNews.com - All Company Technology News Since 1996

Cumberland Pharmaceuticals Inc.

News articles for Cumberland Pharmaceuticals Inc.:

Tuesday, August 5, 2014

  • Cumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results
    NASHVILLE, Tenn., Aug. 5, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2014 financial results. http://photos.prnewswire.com/prnvar/20140505/84325 SUMMARY FINANCIAL RESULTS: During the second quarter 2014, net revenues were $9.8 million, up nearly 38% from the prior year period. ... read more

Tuesday, July 22, 2014

Tuesday, May 13, 2014

  • Cumberland Pharmaceuticals Reports First Quarter 2014 Financial Results
    NASHVILLE, Tenn., May 13, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2014 financial results. During the quarter the Company returned to profitability, launched two new products, and continued ... read more

Wednesday, May 7, 2014

  • Cumberland Pharmaceuticals Launches VaprisolĀ® Promotion
    NASHVILLE, Tenn., May 7, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the launch of its active promotional campaign to support its new Vaprisol(®) product. Cumberland will promote Vaprisol across the United States through its hospital sales force. A National Sales Meeting was convened ... read more

Tuesday, May 6, 2014

Tuesday, April 29, 2014

Friday, March 7, 2014

Tuesday, March 4, 2014

Monday, March 3, 2014

  • Cumberland Pharmaceuticals Acquires VaprisolĀ® from Astellas Pharma US, Inc.
    NASHVILLE, Tenn., March 3, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol(®) from Astellas Pharma US, Inc. Vaprisol(®) is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with hyponatremia. The product was developed and registered by Astellas and ... read more

Thursday, February 27, 2014